Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.00 USD
Change Today -0.39 / -1.07%
Volume 338.9K
ADRO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

aduro biotech inc (ADRO) Snapshot

Open
$36.37
Previous Close
$36.39
Day High
$36.86
Day Low
$35.00
52 Week High
04/16/15 - $49.25
52 Week Low
04/15/15 - $30.60
Market Cap
2.1B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
59.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADURO BIOTECH INC (ADRO)

Related News

No related news articles were found.

aduro biotech inc (ADRO) Related Businessweek News

No Related Businessweek News Found

aduro biotech inc (ADRO) Details

Aduro BioTech, Inc., a clinical-stage immuno-oncology company, focuses on the development of technology platforms designed to stimulate robust and durable immune responses against cancer. Its lead product candidate is CRS-207, which is in a Phase IIb clinical trial for the treatment of metastatic pancreatic cancer and unresectable malignant pleural mesothelioma. The company’s cyclic dinucleotides product candidates are synthetic small molecule immune modulators that target and activate Stimulator of Interferon Genes receptor. Aduro BioTech, Inc. has collaboration agreement with Janssen Biotech, Inc. to develop drugs for the treatment of prostate and lung cancers. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.

50 Employees
Last Reported Date: 04/15/15
Founded in 2000

aduro biotech inc (ADRO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $886.6K
Chief Operating Officer
Total Annual Compensation: $585.9K
Chief Scientific Officer
Total Annual Compensation: $584.9K
Compensation as of Fiscal Year 2014.

aduro biotech inc (ADRO) Key Developments

Aduro BioTech, Inc. Adopts Amended and Restated Bylaws

Effective as of April 20, 2015, Aduro BioTech, Inc. adopted amended and restated bylaws in connection with the closing of the company’s initial public offering of shares of its common stock. The company’s board of directors and stockholders previously approved the restated Bylaws effective as of and contingent upon the closing of the company’s initial public offering.

Aduro BioTech, Inc.(NasdaqGS:ADRO) added to NASDAQ Composite Index

Aduro BioTech, Inc. has been added to Nasdaq Composite Index.

Novartis Accelerates Cancer Immunotherapy Efforts with Aduro Biotech Alliance and Launch of New Immuno-Oncology Research Group

Novartis announced that it is stepping up its efforts to harness the body's immune system to combat cancer. The company has entered into a major multiyear alliance with Aduro Biotech that is focused on the discovery and development of next generation cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway and launched a new immuno-oncology research group led by renowned cancer vaccine expert Glenn Dranoff, MD. The addition of STING agonists adds firepower to Novartis' diverse portfolio of immunotherapies that includes chimeric antigen receptor T-cell (CART) technology and novel checkpoint inhibitors. Currently the CART program, CTL019, is in phase 2 clinical trials and checkpoint inhibitors targeting PD1, LAG3, and TIM3 are expected to enter the clinic in mid-2015. Under the terms of the agreement with Aduro, Novartis will make an upfront payment of $200 million to Aduro and will make an initial equity investment in the company for $25 million, with a commitment for another $25 million equity investment at a future date. Aduro will lead commercialization activities and book sales in the US, with Novartis leading commercialization and recognizing sales in the rest of the world. The companies will share in profits in the US, Japan and major European countries. Novartis will pay Aduro a royalty for sales in the rest of the world.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADRO:US $36.00 USD -0.39

ADRO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $30.10 USD +0.19
Dynavax Technologies Corp $23.31 USD -0.38
Inovio Pharmaceuticals Inc $10.35 USD -0.25
Novavax Inc $8.58 USD -0.07
ZIOPHARM Oncology Inc $10.81 USD -0.395
View Industry Companies
 

Industry Analysis

ADRO

Industry Average

Valuation ADRO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 302.4x
Price/Book 23.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 154.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADURO BIOTECH INC, please visit www.aduro.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.